<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hartung, Hans-Peter</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evolving MS Treatment Strategies</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-29</style></pages><abstract><style  face="normal" font="default" size="100%">The assessment of disease activity and burden has evolved from one based on clinical activity to one based on radiologic criteria (eg, number of new/enlarging T2 lesions, number of gadolinium-enhancing [Gd+] lesions, and brain atrophy/black holes). Treatment has moved from slowing disease progression to treatments (eg, natalizumab, fingolimod, interferon beta-1b [IFN-β-1b]) that improve and sustain function.</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>